Ignite Creation Date:
2024-05-05 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00548964
Status:
COMPLETED
Last Update Posted:
2014-05-23
First Post:
2007-10-24
Brief Title:
Continuation Ketamine in Major Depression
Sponsor:
James Murrough
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
Continuation Intravenous Ketamine in Major Depressive Disorder - Modification Lithium for Relapse Prevention
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
As of May 21st 2012 the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression TRD who respond to an initial series of ketamine infusions Ketamine is a Food and Drug Administration approved anesthetic a drug used to produce loss of consciousness before and during surgery Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None